Compare JPMorgan Equity Premium Income ETF (JEPI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Mesoblast Limited — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.62, while Mesoblast Limited trades at $16.38 (market cap $2.17B). The key difference: Mesoblast Limited is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPI | MESO | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $59.88 | $20.96 |
52-Week Low | $55.29 | $12.88 |
Market Cap | — | $2.17B |
Enterprise Value | — | $2.17B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
